AstraZeneca Plc ended the second quarter with total revenue of $11.4 billion, up by 6% on a reported basis, and by 9% in constant exchange rates (CER). Excluding products developed for the Covid-19 pandemic, the rise was 14% and 17% respectively – figures that underscored the breadth of the company’s product portfolio.
